Citius Pharmaceuticals Inc
Officers & Directors
Leonard Mazur is the cofounder and Vice Chairman of Akrimax Pharmaceuticals, LLC
("Akrimax"), a privately held pharmaceutical company specializing in
producing cardiovascular and general pharmaceutical products. Akrimax was founded
in September 2008 and has successfully launched prescription drugs while acquiring
drugs from major pharmaceutical companies. From January 2005 to May 2012, Mr.
Mazur also co-founded and served as the Chief Operating Officer of Triax Pharmaceuticals
LLC ("Triax"), a specialty pharmaceutical company producing prescription
dermatological drugs. Prior to joining Triax, he was the founder and, from 1995
to 2005, Chief Executive Officer of Genesis Pharmaceutical, Inc. ("Genesis"),
a dermatological products company that marketed its products through dermatologists
offices as well as co-promoting products for major pharmaceutical companies. In
2003, Mr. Mazur successfully sold Genesis to Pierre Fabre, a leading pharmaceutical
company.
Mr. Mazur has extensive sales, marketing and business development experience from
his tenures at Medicis Pharmaceutical Corporation, as executive vice president,
ICN Pharmaceuticals, Inc. as Vice President, Sales & Marketing, Knoll Pharma
(a division of BASF), and Cooper Laboratories, Inc.
Mr. Mazur is a member of the Board of Trustees of Manor College and is a recipient
of the Ellis Island Medal of Honor. Mr. Mazur received both his BA and MBA from
Temple University and has served in the U.S. Marine Corps Reserves. We believe
that Mr. Mazurs entrepreneurial experience and marketing knowledge qualifies
him to serve on our Board of Directors.
Myron Holubiak has extensive experience in managing and advising large and emerging
pharmaceutical and life sciences companies. Mr. Holubiak was the President of
Roche Laboratories, Inc. ("Roche"), a major research-based pharmaceutical
company, from December 1998 to August 2001. Prior to that, he held sales and marketing
positions at Roche during his 19-year tenure. Since September, 2002, Mr. Holubiak
has served on the board of directors and is currently the Chairman of the board
of BioScrip, Inc. ("BioScrip") (Nasdaq: BIOS), a leading national provider
of infusion and home care management solutions. BioScrip partners with physicians,
hospital systems, facilities-based providers, healthcare payors and pharmaceutical
manufacturers to provide patients access to post-acute care services. Since July
2010, Mr. Holubiak has served as a member of the board of directors of Assembly
Biosciences, Inc. ("Assembly") (Nasdaq: ASMB) and its predecessor Ventrus
Biosciences, Inc. ("Ventrus"). Assembly is a biopharmaceutical company
developing innovative treatments for hepatitis B virus infection (HBV) and C.
difficile-associated diarrhea (CDAD), and Ventrus developed treatment for hemorrhoids,
however, phase 3 clinical trials of their compound (which was a new molecular
entity and not previously approved HC/Lido) failed to demonstrate efficacy. After
Ventrus merger with Assembly, this program was discontinued.
Mr. Holubiak is the founder, Chief Executive Officer and a director of Leonard-Meron
Biosciences, Inc. ("LMB"), a private, late-stage specialty pharmaceutical
company focused on the development and commercialization of critical care products
with a concentration on anti-infectives. The Company is developing Mino-Lok™,
an antibiotic lock solution used to treat patients with catheter-related bloodstream
infections, or CRBSIs. In addition, Mr. Holubiak is also a trustee of the Academy
of Managed Care Pharmacy Foundation. Mr. Holubiak received a B.S. in Molecular
Biology and Biophysics from the University of Pittsburg. Although Mr. Holubiak
serves as an officer and director of other pharmaceutical companies, including
BioScrip, Assembly and LMB, none of these companies compete with us. Although
LMB will also utilize 505(b)(2) pathway for approvals, their product focus is
on treating patients catheter-related bloodstream infections which is different
from our focus. Accordingly, we do not believe that Mr. Holubiaks role with other
pharmaceutical companies will result in any conflicts of interest, and that Mr.
Holubiaks industry knowledge and experience managing both large and small firms
qualifies him to serve on our Board of Directors.
Suren Dutia has served as Senior Fellow of the Ewing Mario Kauffman Foundation
since March 2011 and as Senior Fellow of Skandalaris Center for Entrepreneurial
Studies at Washington University, St. Louis since 2013. He has served as a member
of the Advisory Board of Center for Digital Transformation, University of California,
Irvine since May 2012 and as Chairman of the Board of Directors of AccelPath,
LLC since October 2009. From February 2006 to May 2010 Mr. Dutia served as the
Chief Executive Officer of TiE Global, a non-profit organization involved in globally
fostering entrepreneurship. From February 2011 to May 2013, Mr. Dutia served as
a director of LifeProof Cases and from July 2000 to December 2011, he served as
a director of Anvita Health. From 1989 to 1998 Mr. Dutia served as the Chief Executive
Officer and chairman of the board of directors of Xscribe Corporation. Prior to
his positions with Xscibe Corporation, Mr. Dutia held several positions with Dynatech
Corporation, and in addition, he was the president of a medical instruments company.
Previously, Mr. Dutia worked for the U.S. Department of Education. Mr. Dutia received
his B.S. and M.S. degrees in chemical engineering and B.A. in political science
from Washington University, St. Louis. In addition, he obtained an M.B.A. from
University of Dallas. We believe that Mr. Dutias financial management background,
his involvement with start-up companies and his management skills qualifies him
to serve on our Board of Directors.
Citius Pharmaceuticals Inc currently has 23 employees.
|
|
